1. Scrip
  2. >>Business
  3. >>Strategy

Amgen Rebuilt R&D Platform To Focus On Speed And Access

Genetics, AI And Other Tools Assembled Over Past Decade

 
• By Mandy Jackson

The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs. 

Samples of DNA in a multi well plate ready for analysis with DNA results in the background
Amgen's first big investment in genomics was the acquisition of decode in 2012 • Source: Alamy

Amgen, Inc. acknowledged during its business review on 8 February that drug pricing and competitive pressures are growing hurdles for the biopharmaceutical industry through the end of this decade. As a result, Amgen has spent the past decade investing in a research and development platform that is designed to meet those challenges head on.

Some of these are perennial issues, but the long and costly process of developing drugs and launching them with enough...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.